Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03964753 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma

Study acronym: NTNC
StatusRecruiting
PhasePhase 2
Started2019-04-24
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 10, 2023 (before its estimated June 24, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2023-10-06
Study Status v3
Re-verified, no change to tracked fields
2019-08-14
Enrolling by Invitation→Recruiting Study Status, Contacts/Locations v2
Trial statusEnrolling by Invitation→Recruiting
Study sitesdetails revised at 1 of 1 site
2019-05-27
Study Status, Arms and Interventions, Outcome Measures v1
InterventionsNab-paclitaxel and Cisplatin (Drug)→Nab-paclitaxel and Cisplatin (Drug), surgery (Procedure)
Secondary endpoints6 entries, revised
Rate of Operative complicationsComplications Rate of Adverse Event
2019-05-23
Original filing
To verify the role of nab-paclitaxel in neoadjuvant therapy for esophageal squamous cell carcinoma, the investigators designed a prospective, randomized, controlled , multicente phase II trial, to investigate the efficacy and safety of nab-paclitaxel combined with cisplatin as neoadjuvant therapy followed by surgery versus surgery alone for esophageal squamous cell carcinoma.
Trial Details
NCT Number NCT03964753
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 202 participants
Start Date 2019-04-24
Primary Completion 2026-06-24 (estimated)
Study Completion 2026-12-24 (estimated)
Updated on ClinicalTrials.gov 2023-10-10